[Skip to Navigation]
February 1985

Immune Response to a Heat-Inactivated Hepatitis B Vaccine in Patients Undergoing Hemodialysis: Enhancement of the Response by Increasing the Dose of Hepatitis B Surface Antigen From 3 to 27 µg

Author Affiliations

From the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Mr Lelie, Ms de Jong-van Manen, and Drs Dees and Reerink-Brongers), and the Red Cross Blood Bank (Dr Reesink), Amsterdam.

Arch Intern Med. 1985;145(2):305-309. doi:10.1001/archinte.1985.00360020145023

• In a randomized trial, 227 patients undergoing hemodialysis who were seronegative for all markers of hepatitis B virus were Immunized at monthly Intervals with three doses of either 3 μg or 27 μg of heat-Inactivated hepatitis B HB-vaccine (CLB). Five months after the first Injection, 77% of the patients in the 3-μg group and 94% in the 27-μg group manifested antibodies against hepatitis B surface antigen (anti-HBs). At month 12 the proportions of subjects with antl-HBs in the 3-μg and 27-μg groups had dropped to 68% and 87%, respectively. At all times, the differences in the anti-HBs conversion rate between the two treatment groups were significant. These results show that the impaired immune reactivity to hepatitis B vaccines of patients undergoing hemodialysis can be overcome by increasing the dose of the vaccine.

(Arch Intern Med 1985;145:305-309)

Add or change institution